RE:RE:RE:RE:RE:trying to understand?Instead of researching Bioasis's drug/disease combinations, how they work and who the competitors are, poofster captures today's headlines and copy/pastes them here.
The biotechs that are having problems almost all have only one or two "do-or-die" programs. Bioasis has an almost infinite number of drug/disease opportunities and, with collaborators, is pursuing upwards of two dozen of them.
The biotech industry issues are almost exclusively related to new drugs with too many biotechs trying to advance an approach-of-the-day to the disease-of-the-day. Thre are and will continue to be many losers.
Bioasis, on the other hand, is making new use of proven drugs, enzymes and other drugs that need to be delivered to the CNS. If xB3 works, as it always has, then the company can test xB3 drugs against many known targets, already-known biomarkers and the rest of the knowledge bases relating to non-xB3 versions of those drugs.
As a result, the comparisons of Bioasis to most biotechs inferred by poof don't generally apply. For instance, xB3-001 is a version of Herceptin that should act in the brain and body as Herceptin does in the body. That's a much more secure position from which to start compared with the uncertainties of new drug programs at most biotechs.
I believe that poof scans the forum and when he sees a post that provokes a new and improved negative thought, he takes about two minutes to find a headline to fire at Bioasis. It's clumsy, it's lazy and it exposes malicious intentions.
jd